Astellas Pharma
ALPMYNext catalyst
zolbetuximab
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer
Get an email about ALPMY's next catalysts
Track Astellas Pharma (ALPMY) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 12 more upcoming events in our data (Phase 2 readout, Phase 3 readout).See the timeline
13 upcoming, 0 past
zolbetuximab Phase 2 Est. Readout
Estimated primary completion for zolbetuximab trial (NCT03816163) in Pancreatic Cancer. Topline data typically follows completion by weeks to months.
SourceZEN003694 Phase 2 Est. Readout
Estimated primary completion for ZEN003694 trial (NCT04986423) in Metastatic Castration-Resistant Prostate Cancer. Topline data typically follows completion by weeks to months.
SourceEnfortumab Vedotin Phase 2 Est. Readout
Estimated primary completion for Enfortumab Vedotin trial (NCT05756569) in Bladder Squamous Cell Carcinoma. Topline data typically follows completion by weeks to months.
SourceXNW27011 Phase 2 Est. Readout
Estimated primary completion for XNW27011 trial (NCT06792435) in Pancreatic Adenocarcinoma Metastatic. Topline data typically follows completion by weeks to months.
SourceEnzalutamide Phase 3 Est. Readout
Estimated primary completion for Enzalutamide trial (NCT02446405) in Prostatic Neoplasms. Topline data typically follows completion by weeks to months.
SourceEnzalutamide Phase 3 Est. Readout (ENZAMET)
Estimated primary completion for Enzalutamide trial (NCT02446405) in Prostatic Neoplasms. Topline data typically follows completion by weeks to months.
SourceEnfortumab Vedotin Phase 2 Est. Readout
Estimated primary completion for Enfortumab Vedotin trial (NCT06891560) in Adenoid Cystic Carcinoma. Topline data typically follows completion by weeks to months.
SourceEnzalutamide Phase 2 Est. Readout
Estimated primary completion for Enzalutamide trial (NCT02750358) in Breast Cancer. Topline data typically follows completion by weeks to months.
SourceMarket Overview
Stock performance and key metrics
Solifenacin succinate suspension
Urinary Bladder, Overactive
Tacrolimus capsule
Myasthenia Gravis
Vernakalant
Atrial Flutter
CZP
Rheumatoid Arthritis
daclizumab
Kidney Transplantation
basiliximab
Kidney Transplantation
tolterodine ER
Urinary Bladder, Overactive
Corticosteroids
Liver Transplantation
nitrazepam
Sleep Initiation and Maintenance Disorders
Midostaurin
Acute Myeloid Leukemia
Setidegrasib
Pancreatic Cancer
regadenoson
Coronary Artery Disease (CAD)
FK506E (modified release tacrolimus)
Liver Transplantation
Famotidine
Gastroesophageal Reflux
avacincaptad pegol
Geographic Atrophy
Ipragliflozin L-proline
Type 2 Diabetes Mellitus
Sevelamer hydrochloride
Hyperphosphatemia
febuxostat
Gout
Capsaicin
Diabetic Peripheral Neuropathy
cyclosporine microemulsion
Kidney Transplantation
MR4
Kidney Transplantation
Tamuslosin
Urinary Tract Diseases
LoDAC (Low Dose Cytarabine)
Leukemia, Acute Myeloid (AML)
Interferon alfacon-1
Hepatitis C
YM177
Post Operative Pain
Sulfonylurea
Type 2 Diabetes Mellitus
DA
Chronic Kidney Disease
Zolpidem MR
Sleep Initiation and Maintenance Disorders
Mirabegron
Neurogenic Detrusor Overactivity
Micafungin
Candidiasis, Oral
Erlotinib
NSCLC
methylprednisolone and prednisone
Kidney Transplantation
ipragliflozin
Diabetes Mellitus
RSD1235
Atrial Fibrillation
Tacrolimus capsules
Lupus Nephritis
overencapsulated caffeine
Coronary Artery Disease (CAD)
ASP0113
Allogeneic Hematopoietic Cell Transplant
Tamusulosin
Urinary Tract Diseases
alpha glucosidase inhibitor
Type 2 Diabetes Mellitus
Etanercept
Rheumatoid Arthritis
QUTENZA
Painful Diabetic Peripheral Neuropathy (PDPN)
leuprorelin acetate
Prostate Cancer
Plaebo
Rheumatoid Arthritis (RA)
FK506MR capsule
Liver Transplantation
pudexacianinium chloride
Intraoperative Ureter Visualization
Voriconazole
Aspergillosis
Tacrolimus, modified release
Kidney Transplantation
FK506E
Heart Transplantation
Alefacept
Psoriatic Arthritis
Epoetin alfa
Anemia
roxadustat
Hemodialysis Chronic Kidney Disease Patients With Anemia
Ra223
Prostate Cancer
tolterodine
Urinary Bladder, Overactive
Exisulind
NSCLC
Enfortumab vedotin
Metastatic Urothelial Cancer
Fidaxomicin oral suspension
Clostridium Difficile-associated Diarrhea (CDAD)
ASP2138
Gastric Adenocarcinoma
Solifenacin succinate
Urinary Bladder, Overactive
YM178
Urinary Bladder, Overactive
Liposomal Amphotericin B
Candidiasis
Prednisolone
Metastatic Castration Resistant Prostate Cancer
fluconazole
Invasive Candidiasis
nateglinide
Type 2 Diabetes Mellitus
Darbepoetin alfa
Anemia in Chronic Kidney Disease in Non-dialysis Patients
Fezolinetant
Hot Flashes
TRK-100STP high dose
Chronic Renal Failure
Rabbit Anti-Human Thymocyte Globulin
Pancreas-Kidney Transplantation
ASP8825
Restless Legs Syndrome
DPP-4 inhibitor
Type 2 Diabetes Mellitus
Tacrolimus modified-release
Liver Transplantation
YM060
Irritable Bowel Syndrome
Solifenacin
Overactive Bladder
Enzalutamide
Progressive Metastatic Prostate Cancer
Cyclosporine
Heart Diseases
ASP1585
Chronic Kidney Disease Patients on Hemodialysis With Hyperphosphatemia
Goserelin
Prostate Cancer
Certolizumab pegol
Rheumatoid Arthritis
ASP1941
Type 2 Diabetes Mellitus
G-CSF
AML With FLT3 Mutation
ONO-5920
Involutional Osteoporosis
Tacrolimus Cream
Psoriasis
Regadenoson; Optison
Coronary Artery Disease
Disease-modifying antirheumatic drugs (DMARDs)
Rheumatoid Arthritis (RA)
YM150
Arthroplasty, Replacement, Knee
Folinic acid (leucovorin or local equivalent)
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer
tacrolimus ointment
Dermatitis, Atopic
FK949E
Bipolar Disorder
CDP870
Active Rheumatoid Arthritis
linaclotide
Irritable Bowel Syndrome With Constipation (IBS-C)
Minodronic acid hydrate
Involutional Osteoporosis
LHRHA or Surgical Castration
Prostatic Neoplasms
Prograf
Liver Transplantation
isavuconazole
Aspergillosis
OPT-80
Clostridium Difficile
zolbetuximab
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer
YM529/ONO-5920
Osteoporosis
Methylprednisolone
X-Linked Myotubular Myopathy
FK506
Keratoconjunctivitis
Steroids
De Novo Kidney Transplantation
tamsulosin hydrochloride/solifenacin succinate fixed dose combination
Lower Urinary Tract Symptoms
Ramosetron
Vomiting
MMF
Kidney Transplantation
micafungin (Mycamine)
Fungemia
Advagraf
Heart Transplantation
OSI-906
Adrenocortical Carcinoma
FK506MR
Kidney Transplantation
VESIcare®
Urinary Bladder, Overactive
Gilteritinib
Advanced Solid Tumors
Tacrolimus
Dermatitis, Atopic
peficitinib
Psoriasis
FK199B
Sleep Initiation and Maintenance Disorders
tamsulosin hydrochloride OCAS
Benign Prostatic Hyperplasia
caspofungin
Candidiasis, Oral
Androgen deprivation therapy (ADT)
Metastatic Hormone Sensitive Prostate Cancer
Simulect
Kidney Transplantation
degarelix
Prostatic Neoplasms
Tacrolimus (Prograf®)
Rheumatoid Arthritis
Prograf-XL
Liver Transplantation
YM443
Indigestion
ELIGARD
Prostate Cancer
ASP1650
Incurable Platinum Refractory Germ Cell Tumors
YM872 (zonampanel), t-PA (alteplase)
Acute Ischemic Stroke
ASP4070
Rhinitis, Allergic, Seasonal
ASP4901
Benign Prostate Hyperplasia
Tacrolimus Inhalation Aerosol
Asthma
ASP2998
Locally Advanced or Metastatic Malignant Solid Tumors
ASP5541
Prostate Cancer
ASP8062
Fibromyalgia
ASP9831
Non-Alcoholic Steatohepatitis
Isavuconazonium sulfate
Invasive Mucormycosis
FK788
Hepatitis C
OSI-461
Chronic Lymphocytic Leukemia
AGS-1C4D4
Carcinoma, Pancreatic Ductal
ASP1517
Anemia in Chronic Kidney Disease Patients Not on Dialysis
ASP7991
Secondary Hyperparathyroidism
ASP5094
Rheumatoid Arthritis (RA)
ASP4345
Schizophrenia
Prophylactic Regimen B
Glaucoma
FK614
Diabetes Mellitus
ASKP1240
Psoriasis
ZEN003694
Metastatic Castration-Resistant Prostate Cancer
steroids, monoclonal anti-IL2R antibody
Hepatitis C
Prophylactic Regimen A
Glaucoma
YM872 (zonampanel)
Cerebrovascular Accident
YM543
Diabetes Mellitus Type 2
MDV3100
Prostate Cancer
enfortumab vedotin (EV)
Carcinoma, Transitional Cell
ASK8007
Rheumatoid Arthritis
ASP1570
Advanced Solid Tumors
FK463
Candidiasis
ASP6294
Bladder Pain Syndrome
FK778
Kidney Transplantation
ASP8302
Underactive Bladder
ASP2767
Glaucoma
CP-461
Crohn's Disease
Tacrolimus prolonged release
Intestine Transplantation
YM155
Lung Cancer
Anti-IL2R AB
Liver Transplantation
Midazolam
Acute Myeloid Leukemia
tamsulosin hydrochloride
Lower Urinary Tract Symptoms
Lu-PSMA
Metastatic Castration-Resistant Prostate Cancer
tacrolimus modified release (MR)
Liver Transplantation
ASP2151
Herpes Genitalis
ASP8477
Post-Herpetic Neuralgia (PHN)
ASP1707
Endometriosis
ASP7517
Acute Myeloid Leukemia (AML)
ASP8232
Diabetes Mellitus
Idarubicin
Acute Myeloid Leukemia
fezolinetant - reference formulation
Prostate Cancer
trametinib
Prostate Cancer
Clobetasol cream
Vulvar Lichen Sclerosus
ASP546C
Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma
ASP7962
Osteoarthritis of the Knee
ASP2246
Chronic Ischemic Stroke
epirubicin
CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction
AGS-16C3F
Metastatic Renal Cell Carcinoma
ASP3550
Prostatic Neoplasms
VCL-CB01
Acute Lymphoblastic Leukemia
ASP3652
Chronic Abacterial Prostatitis
ASP1128
Acute Kidney Injury (AKI)
linsitinib
Advanced Solid Tumors
YM 155
Prostate Cancer
Reldesemtiv
Chronic Obstructive Pulmonary Disease (COPD)
Bleselumab
Kidney Transplantation
ASP0456
Chronic Constipation
Mycophenolate Mofetil (MMF)
Kidney Transplantation
ASP0819
Fibromyalgia
OSI-211 (Liposomal Lurtotecan)
SCLC
MA09-hRPE
Stargardt's Macular Dystrophy
MK-3475
Bladder Cancer
Enzalutamide capsule
Prostate Cancer
quetiapine extended release (XR)
Major Depressive Disorder
Valacyclovir hydrochloride
Herpes Zoster
warfarin
Atrial Fibrillation
ADT+Docetaxel+Enzalutamide
Prostate Cancer
scAAV9.U7.ACCA
Duchenne Muscular Dystrophy
Lexiscan
Cardiovascular Diseases
Bicalutamide
Prostate Cancer
Rapamycin
Type 1 Diabetes
Leuprolide
Prostate Cancer
TPC
Metastatic Breast Cancer
XNW27011
Pancreatic Adenocarcinoma Metastatic
Androgen Deprivation
Prostate Cancer
Abiraterone
Metastatic Prostate Cancer
Adrenocorticotropic hormone
Prostate Cancer
Beraprost
Renal Insufficiency, Chronic
ASP3082
Metastatic/Locally Advanced Non-Small-Cell Lung Cancer
Trimethoprim and sulfamethoxazole
Kidney Diseases
gadofoveset trisodium
Myocardial Ischemia
GnRH analog
Prostate Cancer
Flutamide
Castration-resistant Prostate Cancer
hydrocortisone acetate
Atopic Dermatitis
Erlotinib Hydrochloride
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Solifenacin succinate suspension | Phase 3 | Urinary Bladder, Overactive | - | - |
Tacrolimus capsule | Phase 3 | Myasthenia Gravis | - | - |
Vernakalant | Phase 3 | Atrial Flutter | - | - |
CZP | Phase 3 | Rheumatoid Arthritis | - | - |
daclizumab | Phase 3 | Kidney Transplantation | - | - |
basiliximab | Phase 3 | Kidney Transplantation | - | - |
tolterodine ER | Phase 3 | Urinary Bladder, Overactive | - | - |
Corticosteroids | Phase 3 | Liver Transplantation | - | - |
nitrazepam | Phase 3 | Sleep Initiation and Maintenance Disorders | - | - |
Midostaurin | Phase 3 | Acute Myeloid Leukemia | - | - |
Setidegrasib | Phase 3 | Pancreatic Cancer | - | - |
regadenoson | Phase 3 | Coronary Artery Disease (CAD) | - | - |
FK506E (modified release tacrolimus) | Phase 3 | Liver Transplantation | - | - |
Famotidine | Phase 3 | Gastroesophageal Reflux | - | - |
avacincaptad pegol | Phase 3 | Geographic Atrophy | - | - |
Ipragliflozin L-proline | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Sevelamer hydrochloride | Phase 3 | Hyperphosphatemia | - | - |
febuxostat | Phase 3 | Gout | - | - |
Capsaicin | Phase 3 | Diabetic Peripheral Neuropathy | - | - |
cyclosporine microemulsion | Phase 3 | Kidney Transplantation | - | - |
MR4 | Phase 3 | Kidney Transplantation | - | - |
Tamuslosin | Phase 3 | Urinary Tract Diseases | - | - |
LoDAC (Low Dose Cytarabine) | Phase 3 | Leukemia, Acute Myeloid (AML) | - | - |
Interferon alfacon-1 | Phase 3 | Hepatitis C | - | - |
YM177 | Phase 3 | Post Operative Pain | - | - |
Sulfonylurea | Phase 3 | Type 2 Diabetes Mellitus | - | - |
DA | Phase 3 | Chronic Kidney Disease | - | - |
Zolpidem MR | Phase 3 | Sleep Initiation and Maintenance Disorders | - | - |
Mirabegron | Phase 3 | Neurogenic Detrusor Overactivity | - | - |
Micafungin | Phase 3 | Candidiasis, Oral | - | - |
Erlotinib | Phase 3 | NSCLC | - | - |
methylprednisolone and prednisone | Phase 3 | Kidney Transplantation | - | - |
ipragliflozin | Phase 3 | Diabetes Mellitus | - | - |
RSD1235 | Phase 3 | Atrial Fibrillation | - | - |
Tacrolimus capsules | Phase 3 | Lupus Nephritis | - | - |
overencapsulated caffeine | Phase 3 | Coronary Artery Disease (CAD) | - | - |
ASP0113 | Phase 3 | Allogeneic Hematopoietic Cell Transplant | - | - |
Tamusulosin | Phase 3 | Urinary Tract Diseases | - | - |
alpha glucosidase inhibitor | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Etanercept | Phase 3 | Rheumatoid Arthritis | - | - |
QUTENZA | Phase 3 | Painful Diabetic Peripheral Neuropathy (PDPN) | - | - |
leuprorelin acetate | Phase 3 | Prostate Cancer | - | - |
Plaebo | Phase 3 | Rheumatoid Arthritis (RA) | - | - |
FK506MR capsule | Phase 3 | Liver Transplantation | - | - |
pudexacianinium chloride | Phase 3 | Intraoperative Ureter Visualization | - | - |
Voriconazole | Phase 3 | Aspergillosis | - | - |
Tacrolimus, modified release | Phase 3 | Kidney Transplantation | - | - |
FK506E | Phase 3 | Heart Transplantation | - | - |
Alefacept | Phase 3 | Psoriatic Arthritis | - | - |
Epoetin alfa | Phase 3 | Anemia | - | - |
roxadustat | Phase 3 | Hemodialysis Chronic Kidney Disease Patients With Anemia | - | - |
Ra223 | Phase 3 | Prostate Cancer | - | - |
tolterodine | Phase 3 | Urinary Bladder, Overactive | - | - |
Exisulind | Phase 3 | NSCLC | - | - |
Enfortumab vedotin | Phase 3 | Metastatic Urothelial Cancer | - | - |
Fidaxomicin oral suspension | Phase 3 | Clostridium Difficile-associated Diarrhea (CDAD) | - | - |
ASP2138 | Phase 3 | Gastric Adenocarcinoma | - | - |
Solifenacin succinate | Phase 3 | Urinary Bladder, Overactive | - | - |
YM178 | Phase 3 | Urinary Bladder, Overactive | - | - |
Liposomal Amphotericin B | Phase 3 | Candidiasis | - | - |
Prednisolone | Phase 3 | Metastatic Castration Resistant Prostate Cancer | - | - |
fluconazole | Phase 3 | Invasive Candidiasis | - | - |
nateglinide | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Darbepoetin alfa | Phase 3 | Anemia in Chronic Kidney Disease in Non-dialysis Patients | - | - |
Fezolinetant | Phase 3 | Hot Flashes | - | - |
TRK-100STP high dose | Phase 3 | Chronic Renal Failure | - | - |
Rabbit Anti-Human Thymocyte Globulin | Phase 3 | Pancreas-Kidney Transplantation | - | - |
ASP8825 | Phase 3 | Restless Legs Syndrome | - | - |
DPP-4 inhibitor | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Tacrolimus modified-release | Phase 3 | Liver Transplantation | - | - |
YM060 | Phase 3 | Irritable Bowel Syndrome | - | - |
Solifenacin | Phase 3 | Overactive Bladder | - | - |
Enzalutamide | Phase 3 | Progressive Metastatic Prostate Cancer | - | - |
Cyclosporine | Phase 3 | Heart Diseases | - | - |
ASP1585 | Phase 3 | Chronic Kidney Disease Patients on Hemodialysis With Hyperphosphatemia | - | - |
Goserelin | Phase 3 | Prostate Cancer | - | - |
Certolizumab pegol | Phase 3 | Rheumatoid Arthritis | - | - |
ASP1941 | Phase 3 | Type 2 Diabetes Mellitus | - | - |
G-CSF | Phase 3 | AML With FLT3 Mutation | - | - |
ONO-5920 | Phase 3 | Involutional Osteoporosis | - | - |
Tacrolimus Cream | Phase 3 | Psoriasis | - | - |
Regadenoson; Optison | Phase 3 | Coronary Artery Disease | - | - |
Disease-modifying antirheumatic drugs (DMARDs) | Phase 3 | Rheumatoid Arthritis (RA) | - | - |
YM150 | Phase 3 | Arthroplasty, Replacement, Knee | - | - |
Folinic acid (leucovorin or local equivalent) | Phase 3 | Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer | - | - |
tacrolimus ointment | Phase 3 | Dermatitis, Atopic | - | - |
FK949E | Phase 3 | Bipolar Disorder | - | - |
CDP870 | Phase 3 | Active Rheumatoid Arthritis | - | - |
linaclotide | Phase 3 | Irritable Bowel Syndrome With Constipation (IBS-C) | - | - |
Minodronic acid hydrate | Phase 3 | Involutional Osteoporosis | - | - |
LHRHA or Surgical Castration | Phase 3 | Prostatic Neoplasms | - | - |
Prograf | Phase 3 | Liver Transplantation | - | - |
isavuconazole | Phase 3 | Aspergillosis | - | - |
OPT-80 | Phase 3 | Clostridium Difficile | - | - |
zolbetuximab | Phase 3 | Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer | - | - |
YM529/ONO-5920 | Phase 3 | Osteoporosis | - | - |
Methylprednisolone | Phase 3 | X-Linked Myotubular Myopathy | - | - |
FK506 | Phase 3 | Keratoconjunctivitis | - | - |
Steroids | Phase 3 | De Novo Kidney Transplantation | - | - |
tamsulosin hydrochloride/solifenacin succinate fixed dose combination | Phase 3 | Lower Urinary Tract Symptoms | - | - |
Ramosetron | Phase 3 | Vomiting | - | - |
MMF | Phase 3 | Kidney Transplantation | - | - |
micafungin (Mycamine) | Phase 3 | Fungemia | - | - |
Advagraf | Phase 3 | Heart Transplantation | - | - |
OSI-906 | Phase 3 | Adrenocortical Carcinoma | - | - |
FK506MR | Phase 3 | Kidney Transplantation | - | - |
VESIcare® | Phase 3 | Urinary Bladder, Overactive | - | - |
Gilteritinib | Phase 3 | Advanced Solid Tumors | - | - |
Tacrolimus | Phase 3 | Dermatitis, Atopic | - | - |
peficitinib | Phase 3 | Psoriasis | - | - |
FK199B | Phase 3 | Sleep Initiation and Maintenance Disorders | - | - |
tamsulosin hydrochloride OCAS | Phase 3 | Benign Prostatic Hyperplasia | - | - |
caspofungin | Phase 3 | Candidiasis, Oral | - | - |
Androgen deprivation therapy (ADT) | Phase 3 | Metastatic Hormone Sensitive Prostate Cancer | - | - |
Simulect | Phase 3 | Kidney Transplantation | - | - |
degarelix | Phase 3 | Prostatic Neoplasms | - | - |
Tacrolimus (Prograf®) | Phase 3 | Rheumatoid Arthritis | - | - |
Prograf-XL | Phase 3 | Liver Transplantation | - | - |
YM443 | Phase 3 | Indigestion | - | - |
ELIGARD | Phase 2 | Prostate Cancer | - | - |
ASP1650 | Phase 2 | Incurable Platinum Refractory Germ Cell Tumors | - | - |
YM872 (zonampanel), t-PA (alteplase) | Phase 2 | Acute Ischemic Stroke | - | - |
ASP4070 | Phase 2 | Rhinitis, Allergic, Seasonal | - | - |
ASP4901 | Phase 2 | Benign Prostate Hyperplasia | - | - |
Tacrolimus Inhalation Aerosol | Phase 2 | Asthma | - | - |
ASP2998 | Phase 2 | Locally Advanced or Metastatic Malignant Solid Tumors | - | - |
ASP5541 | Phase 2 | Prostate Cancer | - | - |
ASP8062 | Phase 2 | Fibromyalgia | - | - |
ASP9831 | Phase 2 | Non-Alcoholic Steatohepatitis | - | - |
Isavuconazonium sulfate | Phase 2 | Invasive Mucormycosis | - | - |
FK788 | Phase 2 | Hepatitis C | - | - |
OSI-461 | Phase 2 | Chronic Lymphocytic Leukemia | - | - |
AGS-1C4D4 | Phase 2 | Carcinoma, Pancreatic Ductal | - | - |
ASP1517 | Phase 2 | Anemia in Chronic Kidney Disease Patients Not on Dialysis | - | - |
ASP7991 | Phase 2 | Secondary Hyperparathyroidism | - | - |
ASP5094 | Phase 2 | Rheumatoid Arthritis (RA) | - | - |
ASP4345 | Phase 2 | Schizophrenia | - | - |
Prophylactic Regimen B | Phase 2 | Glaucoma | - | - |
FK614 | Phase 2 | Diabetes Mellitus | - | - |
ASKP1240 | Phase 2 | Psoriasis | - | - |
ZEN003694 | Phase 2 | Metastatic Castration-Resistant Prostate Cancer | - | - |
steroids, monoclonal anti-IL2R antibody | Phase 2 | Hepatitis C | - | - |
Prophylactic Regimen A | Phase 2 | Glaucoma | - | - |
YM872 (zonampanel) | Phase 2 | Cerebrovascular Accident | - | - |
YM543 | Phase 2 | Diabetes Mellitus Type 2 | - | - |
MDV3100 | Phase 2 | Prostate Cancer | - | - |
enfortumab vedotin (EV) | Phase 2 | Carcinoma, Transitional Cell | - | - |
ASK8007 | Phase 2 | Rheumatoid Arthritis | - | - |
ASP1570 | Phase 2 | Advanced Solid Tumors | - | - |
FK463 | Phase 2 | Candidiasis | - | - |
ASP6294 | Phase 2 | Bladder Pain Syndrome | - | - |
FK778 | Phase 2 | Kidney Transplantation | - | - |
ASP8302 | Phase 2 | Underactive Bladder | - | - |
ASP2767 | Phase 2 | Glaucoma | - | - |
CP-461 | Phase 2 | Crohn's Disease | - | - |
Tacrolimus prolonged release | Phase 2 | Intestine Transplantation | - | - |
YM155 | Phase 2 | Lung Cancer | - | - |
Anti-IL2R AB | Phase 2 | Liver Transplantation | - | - |
Midazolam | Phase 2 | Acute Myeloid Leukemia | - | - |
tamsulosin hydrochloride | Phase 2 | Lower Urinary Tract Symptoms | - | - |
Lu-PSMA | Phase 2 | Metastatic Castration-Resistant Prostate Cancer | - | - |
tacrolimus modified release (MR) | Phase 2 | Liver Transplantation | - | - |
ASP2151 | Phase 2 | Herpes Genitalis | - | - |
ASP8477 | Phase 2 | Post-Herpetic Neuralgia (PHN) | - | - |
ASP1707 | Phase 2 | Endometriosis | - | - |
ASP7517 | Phase 2 | Acute Myeloid Leukemia (AML) | - | - |
ASP8232 | Phase 2 | Diabetes Mellitus | - | - |
Idarubicin | Phase 2 | Acute Myeloid Leukemia | - | - |
fezolinetant - reference formulation | Phase 2 | Prostate Cancer | - | - |
trametinib | Phase 2 | Prostate Cancer | - | - |
Clobetasol cream | Phase 2 | Vulvar Lichen Sclerosus | - | - |
ASP546C | Phase 2 | Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma | - | - |
ASP7962 | Phase 2 | Osteoarthritis of the Knee | - | - |
ASP2246 | Phase 2 | Chronic Ischemic Stroke | - | - |
epirubicin | Phase 2 | CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction | - | - |
AGS-16C3F | Phase 2 | Metastatic Renal Cell Carcinoma | - | - |
ASP3550 | Phase 2 | Prostatic Neoplasms | - | - |
VCL-CB01 | Phase 2 | Acute Lymphoblastic Leukemia | - | - |
ASP3652 | Phase 2 | Chronic Abacterial Prostatitis | - | - |
ASP1128 | Phase 2 | Acute Kidney Injury (AKI) | - | - |
linsitinib | Phase 2 | Advanced Solid Tumors | - | - |
YM 155 | Phase 2 | Prostate Cancer | - | - |
Reldesemtiv | Phase 2 | Chronic Obstructive Pulmonary Disease (COPD) | - | - |
Bleselumab | Phase 2 | Kidney Transplantation | - | - |
ASP0456 | Phase 2 | Chronic Constipation | - | - |
Mycophenolate Mofetil (MMF) | Phase 2 | Kidney Transplantation | - | - |
ASP0819 | Phase 2 | Fibromyalgia | - | - |
OSI-211 (Liposomal Lurtotecan) | Phase 2 | SCLC | - | - |
MA09-hRPE | Phase 2 | Stargardt's Macular Dystrophy | - | - |
MK-3475 | Phase 2 | Bladder Cancer | - | - |
Enzalutamide capsule | Phase 2 | Prostate Cancer | - | - |
quetiapine extended release (XR) | Phase 2 | Major Depressive Disorder | - | - |
Valacyclovir hydrochloride | Phase 2 | Herpes Zoster | - | - |
warfarin | Phase 2 | Atrial Fibrillation | - | - |
ADT+Docetaxel+Enzalutamide | Phase 2 | Prostate Cancer | - | - |
scAAV9.U7.ACCA | Phase 2 | Duchenne Muscular Dystrophy | - | - |
Lexiscan | Phase 2 | Cardiovascular Diseases | - | - |
Bicalutamide | Phase 2 | Prostate Cancer | - | - |
Rapamycin | Phase 2 | Type 1 Diabetes | - | - |
Leuprolide | Phase 2 | Prostate Cancer | - | - |
TPC | Phase 2 | Metastatic Breast Cancer | - | - |
XNW27011 | Phase 2 | Pancreatic Adenocarcinoma Metastatic | - | - |
Androgen Deprivation | Phase 2 | Prostate Cancer | - | - |
Abiraterone | Phase 2 | Metastatic Prostate Cancer | - | - |
Adrenocorticotropic hormone | Phase 2 | Prostate Cancer | - | - |
Beraprost | Phase 2 | Renal Insufficiency, Chronic | - | - |
ASP3082 | Phase 2 | Metastatic/Locally Advanced Non-Small-Cell Lung Cancer | - | - |
Trimethoprim and sulfamethoxazole | Phase 2 | Kidney Diseases | - | - |
gadofoveset trisodium | Phase 2 | Myocardial Ischemia | - | - |
GnRH analog | Phase 2 | Prostate Cancer | - | - |
Flutamide | Phase 2 | Castration-resistant Prostate Cancer | - | - |
hydrocortisone acetate | Phase 2 | Atopic Dermatitis | - | - |
Erlotinib Hydrochloride | Phase 2 | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | - | - |
Atrial Flutter
2 drugs in this indication
geographic atrophy
1 drug in this indication
Rhinitis, Allergic, Seasonal
1 drug in this indication
Asthma
1 drug in this indication
Benign Prostate Hyperplasia
1 drug in this indication
Pancreatic Cancer
1 drug in this indication
Rheumatoid Arthritis
1 drug in this indication
Locally advanced/metastatic bladder cancer
1 drug in this indication
Previously treated KRAS G12D-mutated advanced non-small cell lung cancer
1 drug in this indication
Clostridium Difficile
1 drug in this indication
Kidney Transplantation
1 drug in this indication
Incurable Platinum Refractory Germ Cell Tumors
1 drug in this indication
Post Operative Pain
1 drug in this indication
Fungemia
1 drug in this indication
NSCLC
1 drug in this indication
KRAS G12D-mutated advanced non-small cell lung cancer
1 drug in this indication
Urinary Bladder, Overactive
1 drug in this indication
Acute Ischemic Stroke
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Astellas Pharma's drug pipeline?→
CatalystAlert tracks 213 drug candidates in Astellas Pharma's (ALPMY) pipeline across Phase 3, Phase 2. Its lead program is Enfortumab vedotin (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Astellas Pharma's next FDA catalyst?→
Astellas Pharma's (ALPMY) next tracked catalyst is a Phase 2 readout expected October 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ALPMY biotech catalysts?→
Add ALPMY to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Astellas Pharma's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.